Arcutis : ZORYVE Cream 0.15% Improves Atopic Dermatitis Across Skin Types In Phase 3 Trials
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Arcutis Biotherapeutics Inc.’s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ethnicity, and Fitzpatrick skin types, as per subgroup analysis results from the Phas
:max_bytes(150000):strip_icc():format(jpeg)/books-techanalysis-413943ab35a940b880900d27324f847b.jpg "Top 7 Books to Learn Technical Analysis")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-13181780681-1a53682681b44b55a60086057b16324c.jpg "10 Reasons to Use Your Credit Card")
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-Small-Business-Insurance-Cost-f33f850a0ca945528045e78883f336fd.jpg "Small Business Insurance Cost")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1369747895-7e5dc6dc82804688b888709e14a30cac.jpg "An Options Strategy for Trading Market Bottoms")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-580503469-78faed37ed3c4d36b9ff954db9d9db31.jpg "How Certificate of Deposit (CDs) Maturities Work")